The Investment Column: SkyePharma
Friday 03 September 1999
The attraction of the group, which aims to be a specialist in drug delivery mechanisms, is the promise of riding on the back of the earnings streams of major pharmaceuticals groups employing its services. The star is Paxil CR, a variation of a SmithKline Beecham drug. But the treatment has not yet gone to market because SmithKline's existing Paxil drug has retained patent protection.
No wonder SkyePharma is broadening its portfolio. It has gained two new products this year with the acquisition in March of California-based DepoTech. DepoCyte, a meningitis treatment in which it has a 50 per cent stake of royalties, hit the market in May; its sales - pounds 1.3m in the period - are meeting expectations, but it will not be a blockbuster. DepoMorphine, a painkiller for hip surgery, has a potentially larger market but is still in trials.
The half-year sales hike followed rises in research and development income and royalties. After a pounds 2m hit from the cost of listing in the US, underlying losses narrowed from pounds 7.5m to pounds 3.8m in the first half. Analysts expect a full-year loss of pounds 11m, with maiden profits in the first half next year.
With the group lacking a deal to provide guaranteed and substantial revenues, the shares are risky.
- 1 Malaysian cyclist could face disciplinary action after 'Save Gaza' gloves protest
- 2 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 3 McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
- 4 Students offered grants if they tweet pro-Israeli propaganda
- 5 Satellite full of sexually experimental geckos adrift in space, Russia loses control of mission
Israel-Gaza conflict: Israeli targeting policy under scrutiny after shellfire hits a mother and child, a school full of refugees and a doctor’s home
Iraq crisis: Isis orders Mosul shop keepers to cover mannequins
Comic Con 2014 attendees
Students offered grants if they tweet pro-Israeli propaganda
McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
Malaysia Airlines MH17 crash: Vladimir Putin is given 'one last chance' to end hostilities in Ukraine
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
The truth about conspiracy theories is that some require considering
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
iJobs Money & Business
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...
£280 - £300 per day + competitive: Orgtel: Test Analyst, Edinburgh, Credit Ris...
£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...